EMMAEmmaus Life Sciences, Inc.

About Emmaus Life Sciences, Inc. (EMMA)

Emmaus Life Sciences, Inc. (EMMA) is a Biotechnology company headquartered in Torrance, CA, United States whose shares trade over-the-counter on the OTCQB tier.

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease.

Products and services

Emmaus Life Sciences, Inc. is a commercial-stage biopharmaceutical company and leader in the treatment of sickle cell disease. The company currently markets and sells Endari® (L-glutamine oral powder), indicated to reduce the acute complications of sickle cell disease in adults and children 5 years and older, in the U.S., U.A.E., Kuwait, Qatar, Bahrain, Oman and is pursuing marketing authorization for Endari® in other GCC countries. The company is also engaged in the discovery and development of innovative treatments and therapies for certain rare and orphan diseases as well as those affecting larger populations, such as certain cancers. For more information, please visit www.emmausmedical.com.

EMMA key facts

Ticker symbol

EMMA

Market tier

OTCQB

Sector

Healthcare

Industry

Biotechnology

Headquarters

Torrance, CA, United States

Country of incorporation

US

Year of incorporation

1987

Employees

21

Estimated market cap

$989.9K (as of Apr 11, 2025)

Shares outstanding

63,865,571

Reporting standard

U.S. Reporting: SEC Reporting

Audit status

Audited

Fiscal year end

12/31

Emmaus Life Sciences, Inc. leadership

• Willis C. Lee — CEO
• Yasushi Nagasaki — CFO
• Dale E Short — Secretary
• Charles Stark — Vice President, CTO

Explore more: Biotechnology stocks · Healthcare sector · OTCQB stocks · OTC stocks starting with E